Annovis Bio, Inc. (ANVS)
NYSE · Healthcare · Biotechnology
$1.20+1.69%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $51.2M
- 52-week range
- $1.04 – $5.50
- 52-week change
- −47.79%
- EPS (trailing)
- −$1.75
Fiscal year to Dec 2025
- Revenue
- $0K
- Net income
- −$28.9M
- Diluted EPS
- −$1.40
From the company’s annual report on SEC EDGAR.
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Headquarters: Malvern, United States · 7 employees · annovisbio.com